Michael Brada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael Brada has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Helen Forbes
Department of Radiation Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust Wirral, United Kingdom
3 shared publicationsSusan Ashley
Department of Radiation Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust Wirral, United Kingdom
3 shared publicationsJohn Fenwick
Department of Radiation Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust Wirral, United Kingdom
2 shared publicationsAnthony Pope
Department of Radiation Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK
1 shared publicationBrian Haylock
From the University of Liverpool, Department of Molecular and Clinical Cancer Medicine, Liverpool; Department of Radiation Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Bebbington, Wirral
1 shared publicationChristine Ball
National Clinical Analysis and Specialised Applications Team (NATCANSAT), Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom
1 shared publication
Latest Publications
- 24 May 2022
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 17 (6) , e56-e57
Robust Comprehensive Dataset Provides Pause for Thought
- 24 May 2022
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 17 (6) , e56-e57
Robust Comprehensive Dataset Provides Pause for Thought
- Open Access
- 31 January 2022
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 17 (4) , 532-543
Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters
- 31 January 2022
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 17 (4) , 532-543
Open AccessImproving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters
- 1 March 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 132, 204-210
Improving outcomes in non-small cell lung cancer; population analysis of radical radiotherapy
- 1 March 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 132, 204-210
Improving outcomes in non-small cell lung cancer; population analysis of radical radiotherapy
- 6 February 2015
- Published by Elsevier in Clinical Oncology
- Vol. 27 (5) , 316-323
New Developments in Intracranial Stereotactic Radiotherapy for Metastases
- 6 February 2015
- Published by Elsevier in Clinical Oncology
- Vol. 27 (5) , 316-323
New Developments in Intracranial Stereotactic Radiotherapy for Metastases
- 1 February 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 114 (2) , 135-137
SABR in NSCLC – The beginning of the end or the end of the beginning?
- 1 February 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 114 (2) , 135-137
SABR in NSCLC – The beginning of the end or the end of the beginning?
- 1 May 2014
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- No. 34,p. e89-e94
Is Current Technology Improving Outcomes with Radiation Therapy for Gliomas?
Radiotherapy (RT) remains the principal component of glioma treatment, and three-dimensional conformal RT (3DCRT) is the current standard of RT delivery. Advances in imaging and in RT technology have enabled more precise treatment to defined targets combined with better means of avoiding critical normal structures, and this is complemented by intensive quality assurance, which includes on-treatment imaging. The refinements of 3DCRT include intensity modulated RT (IMRT), arcing IMRT, and high-precision conformal RT, formerly described as “stereotactic,” which can be delivered using a linear accelerator or other specialized equipment. Although proton therapy uses heavy charged particles, the principal application can also be considered as refinement of 3DCRT. The technologies generally improve the dose differential between the tumor and normal tissue and enable more dose-intensive treatments. However, these have not translated into improved survival outcome in patients with low- and high-grade gliomas. More intensive altered fractionation regimens have also failed to show survival benefit. Nevertheless, novel technologies enable better sparing of normal tissue and selective avoidance of critical structures, and these need to be explored further to improve the quality of life of patients with gliomas. Principal clinical advance in RT has been the recognition that less intensive treatments are beneficial for patients with adverse prognosis high-grade gliomas. We conclude that the principal gain of modern RT technology is more likely to emerge as a reduction in treatment related toxicity rather than as an improvement in overall survival; the optimal avoidance strategies remain to be defined.
- 1 May 2014
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- No. 34,p. e89-e94
Is Current Technology Improving Outcomes with Radiation Therapy for Gliomas?
Radiotherapy (RT) remains the principal component of glioma treatment, and three-dimensional conformal RT (3DCRT) is the current standard of RT delivery. Advances in imaging and in RT technology have enabled more precise treatment to defined targets combined with better means of avoiding critical normal structures, and this is complemented by intensive quality assurance, which includes on-treatment imaging. The refinements of 3DCRT include intensity modulated RT (IMRT), arcing IMRT, and high-precision conformal RT, formerly described as “stereotactic,” which can be delivered using a linear accelerator or other specialized equipment. Although proton therapy uses heavy charged particles, the principal application can also be considered as refinement of 3DCRT. The technologies generally improve the dose differential between the tumor and normal tissue and enable more dose-intensive treatments. However, these have not translated into improved survival outcome in patients with low- and high-grade gliomas. More intensive altered fractionation regimens have also failed to show survival benefit. Nevertheless, novel technologies enable better sparing of normal tissue and selective avoidance of critical structures, and these need to be explored further to improve the quality of life of patients with gliomas. Principal clinical advance in RT has been the recognition that less intensive treatments are beneficial for patients with adverse prognosis high-grade gliomas. We conclude that the principal gain of modern RT technology is more likely to emerge as a reduction in treatment related toxicity rather than as an improvement in overall survival; the optimal avoidance strategies remain to be defined.